Thermoterapy effective and safer than miltefosine in the treatment of cutaneous leishmaniasis in Colombia
In Colombia, pentavalent antimonials and miltefosine are the drugs of choice for the treatment of cutaneous leishmaniasis; however, their toxicity, treatment duration, (treatment adherence problems), cost, and decreased parasite sensitivity make the search for alternative treatments of American cutaneous leishmaniasis necessary. Based on the results found in a controlled, open, randomized, phase III clinical trial, the efficacy and safety of miltefosine was compared to that of thermotherapy for the treatment of cutaneous leishmaniasis in Colombia. Adult patients from the Colombian army participated in the study; they received either 50 mg of miltefosine three times per day for 28 days by the oral route (n = 145) or a thermotherapy (Thermomed®) application of 50 °C for 30 seconds over the lesion and surrounding area (n = 149). Both groups were comparable with respect to their sociodemographic, clinical, and parasitological characteristics. The efficacy of miltefosine by protocol and by intention to treat was 70% (85/122 patients) and 69% (85/145 patients), respectively. The adverse effects were primarily gastrointestinal for miltefosine and pain at the lesion site after treatment for thermotherapy. No statistically significant difference was found in the efficacy analysis (intention to treat and protocol) between the two treatments. ClinicalTrials.gov: NCT00471705.
Main Authors: | , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Instituto de Medicina Tropical de São Paulo
2013
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46652013000300197 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S0036-46652013000300197 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S0036-466520130003001972013-05-21Thermoterapy effective and safer than miltefosine in the treatment of cutaneous leishmaniasis in ColombiaLópez,LilianaCruz,ClaudiaGodoy,GonzaloM. Robledo,SaraD. Vélez,Iván Thermotherapy Cutaneous leishmaniasis Miltefosine Treatment Efficacy Safety In Colombia, pentavalent antimonials and miltefosine are the drugs of choice for the treatment of cutaneous leishmaniasis; however, their toxicity, treatment duration, (treatment adherence problems), cost, and decreased parasite sensitivity make the search for alternative treatments of American cutaneous leishmaniasis necessary. Based on the results found in a controlled, open, randomized, phase III clinical trial, the efficacy and safety of miltefosine was compared to that of thermotherapy for the treatment of cutaneous leishmaniasis in Colombia. Adult patients from the Colombian army participated in the study; they received either 50 mg of miltefosine three times per day for 28 days by the oral route (n = 145) or a thermotherapy (Thermomed®) application of 50 °C for 30 seconds over the lesion and surrounding area (n = 149). Both groups were comparable with respect to their sociodemographic, clinical, and parasitological characteristics. The efficacy of miltefosine by protocol and by intention to treat was 70% (85/122 patients) and 69% (85/145 patients), respectively. The adverse effects were primarily gastrointestinal for miltefosine and pain at the lesion site after treatment for thermotherapy. No statistically significant difference was found in the efficacy analysis (intention to treat and protocol) between the two treatments. ClinicalTrials.gov: NCT00471705.info:eu-repo/semantics/openAccessInstituto de Medicina Tropical de São PauloRevista do Instituto de Medicina Tropical de São Paulo v.55 n.3 20132013-06-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46652013000300197en10.1590/S0036-46652013000300011 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
López,Liliana Cruz,Claudia Godoy,Gonzalo M. Robledo,Sara D. Vélez,Iván |
spellingShingle |
López,Liliana Cruz,Claudia Godoy,Gonzalo M. Robledo,Sara D. Vélez,Iván Thermoterapy effective and safer than miltefosine in the treatment of cutaneous leishmaniasis in Colombia |
author_facet |
López,Liliana Cruz,Claudia Godoy,Gonzalo M. Robledo,Sara D. Vélez,Iván |
author_sort |
López,Liliana |
title |
Thermoterapy effective and safer than miltefosine in the treatment of cutaneous leishmaniasis in Colombia |
title_short |
Thermoterapy effective and safer than miltefosine in the treatment of cutaneous leishmaniasis in Colombia |
title_full |
Thermoterapy effective and safer than miltefosine in the treatment of cutaneous leishmaniasis in Colombia |
title_fullStr |
Thermoterapy effective and safer than miltefosine in the treatment of cutaneous leishmaniasis in Colombia |
title_full_unstemmed |
Thermoterapy effective and safer than miltefosine in the treatment of cutaneous leishmaniasis in Colombia |
title_sort |
thermoterapy effective and safer than miltefosine in the treatment of cutaneous leishmaniasis in colombia |
description |
In Colombia, pentavalent antimonials and miltefosine are the drugs of choice for the treatment of cutaneous leishmaniasis; however, their toxicity, treatment duration, (treatment adherence problems), cost, and decreased parasite sensitivity make the search for alternative treatments of American cutaneous leishmaniasis necessary. Based on the results found in a controlled, open, randomized, phase III clinical trial, the efficacy and safety of miltefosine was compared to that of thermotherapy for the treatment of cutaneous leishmaniasis in Colombia. Adult patients from the Colombian army participated in the study; they received either 50 mg of miltefosine three times per day for 28 days by the oral route (n = 145) or a thermotherapy (Thermomed®) application of 50 °C for 30 seconds over the lesion and surrounding area (n = 149). Both groups were comparable with respect to their sociodemographic, clinical, and parasitological characteristics. The efficacy of miltefosine by protocol and by intention to treat was 70% (85/122 patients) and 69% (85/145 patients), respectively. The adverse effects were primarily gastrointestinal for miltefosine and pain at the lesion site after treatment for thermotherapy. No statistically significant difference was found in the efficacy analysis (intention to treat and protocol) between the two treatments. ClinicalTrials.gov: NCT00471705. |
publisher |
Instituto de Medicina Tropical de São Paulo |
publishDate |
2013 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46652013000300197 |
work_keys_str_mv |
AT lopezliliana thermoterapyeffectiveandsaferthanmiltefosineinthetreatmentofcutaneousleishmaniasisincolombia AT cruzclaudia thermoterapyeffectiveandsaferthanmiltefosineinthetreatmentofcutaneousleishmaniasisincolombia AT godoygonzalo thermoterapyeffectiveandsaferthanmiltefosineinthetreatmentofcutaneousleishmaniasisincolombia AT mrobledosara thermoterapyeffectiveandsaferthanmiltefosineinthetreatmentofcutaneousleishmaniasisincolombia AT dvelezivan thermoterapyeffectiveandsaferthanmiltefosineinthetreatmentofcutaneousleishmaniasisincolombia |
_version_ |
1756379872098254848 |